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Circulating nucleic acids (CNAs), for example, 
circulating tumor DNA (ctDNA) and circulating 
microRNA (miRNA), represent promising bio-
markers in several diseases including cancer. They 
can be isolated from many body fluids, such as 
blood, saliva, and urine. Also ascites, cerebrospi-
nal fluids, and pleural effusion may be considered 
as a source of CNAs, but with several and intrinsic 
limitations. Therefore, blood withdrawal repre-
sents one of the best sources for CNAs due to the 
very simple and minimally invasive way of sam-
pling. Moreover, it can be repeated at different 
time points, giving the opportunity for a real-time 
monitoring of the disease.
CNAs are spread from both cancer and normal 
cells, but in cancer patients their concentrations are 
greater [1, 2]. Nevertheless, the mechanisms under-
lying their release are not fully understood. Some 
evidences show that CNAs can be released through 
a passive mechanism; indeed, infiltrating phago-
cytes clear apoptotic or necrotic cells under normal 
physiologic circumstances. This does not happen 
efficiently within the tumoral mass, leading to the 
accumulation of cellular debris and its inevitable 
release into the circulation. Another possible way 
of CNAs release could be through extracellular 
vesicles, such as exosomes. In this case, CNAs are 
packed inside exosome and actively secreted by 
cells. This seems to be more realistic for miRNAs, 
whereas for DNA there are still conflicting data.
 Circulating Tumor DNA (ctDNA)
Circulating cell-free DNA (cfDNA) is highly 
fragmented, and therefore it represents a chal-
lenging analyte. It has been shown that the length 
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of cfDNA strands is often between 200 and 180 
base pairs, suggesting that apoptosis likely pro-
duces the majority of cfDNA in circulation [3]. 
Circulating tumor DNA (ctDNA) is part of the 
cfDNA deriving from the tumor mass. The easi-
est way to identify the ctDNA is to investigate the 
presence of somatic driver mutations, which, by 
definition, can be exclusively found on tumor. 
Nevertheless, several methods have shown that 
the fraction of ctDNA varies greatly, between 
0.01% and more than 90% [3]. Moreover, differ-
ent tumor types do not release the same amount 
of ctDNA, and, even in patients with the same 
disease, the concentration of ctDNA may vary 
consistently [4].
Several pre-analytical variables, such as blood 
collection and handling, ctDNA extraction proto-
cols, and storage temperature may affect the quan-
tity and quality of ctDNA fragments in a sample 
[5–8]. As previously mentioned, blood represents 
the most used source for ctDNA. Nevertheless, 
there is a big question: serum or plasma?
In the majority of clinical trails, EDTA con-
taining tubes are used for blood collection (4–9 
[9]). Using these tubes clotting is inhibited, and 
thus it is possible to recover plasma that represent 
the matrix of choice for ctDNA extraction. 
Actually also serum can be used as a matrix to 
isolate ctDNA; indeed, it has been reported that 
the amount of ctDNA in serum can be 2–24 times 
higher than in plasma. This can be a consequence 
of the clotting process that causes white blood 
cells (WBCs) breaking, finally leading to the 
release of wild-type DNA. This contamination 
causes a further dilution of the tumor-specific 
DNA, making it even more difficult to detect. 
However, it has been reported that in some cases 
it might be advantageous to analyze both serum 
and plasma, as this increases the chances to detect 
the specific mutation [10].
Another important pre-analytical aspect is the 
time that elapses between the withdrawal and its 
processing for plasma recovery. Indeed, the more 
the time passes, the more is the risk of WBCs 
lysis, leading again to ctDNA contamination with 
wild-type background DNA. Moreover ctDNA is 
associated with a high turnover (15 min half- 
life), and therefore after blood collection, it is 
recommended to proceed with plasma prepara-
tion by centrifugation within 1 h [11]. Plasma can 
be stored for a long period at −20 °C or immedi-
ately processed for ctDNA extraction.
ctDNA extraction can be performed through 
different kits; recently, Sorber L et al. [12] have 
compared the isolation efficiency of the most used 
kit, the QIAamp circulating nucleic acid kit 
(QIA), with four other cfDNA isolation kits: the 
PME free-circulating DNA Extraction Kit (PME), 
the Maxwell RSC ccfDNA Plasma Kit (RSC), the 
EpiQuick Circulating Cell-Free DNA Isolation 
Kit (EQ), and two consecutive versions of the 
NEXTprep-Mag cfDNA Isolation Kit (NpMV1/2). 
A total of ten samples were used, and five of them 
harbored KRAS mutations. In the study, the 
detection of KRAS mutation and total cell-free 
DNA concentration were performed with droplet 
digital PCR, whereas real-time PCR was used to 
evaluate cfDNA integrity. They showed that QIA 
and the RSC kits displayed similar isolation effi-
ciencies, whereas the yield generated by the PME 
and NpMV2 kits was significantly lower [12]. 
Interestingly, Sonnenberg et al. developed an 
electrokinetic technique that allowed rapid isola-
tion of cfDNA directly from blood [13, 14].
Following extraction, another important issue 
is the quantification method. There is no standard-
ization of the quantification method, which can 
lead to different results. The most commonly used 
techniques include spectrophotometric methods, 
fluorescent dyes, or quantitative PCR- based meth-
ods [15]. The identification of a reliable and effi-
cient method for cfDNA quantification is 
fundamental for the clinical evaluation of ctDNA 
as a liquid biopsy in order to obtain consistent 
data, comparable between laboratories.
Plasma DNA investigation can be achieved 
through two different analytical approaches: a 
targeted approach and an untargeted approach 
(Fig. 6.1). The targeted approach relies on the 
possibility to analyze known genetic mutations 
that occurs in hotspot region of specific genes 
with implications for therapy decisions; this is 
the case, for example, of KRAS, EGFR, and 
BRAF genes in lung, colon, and melanoma 
tumors, respectively. Among these methods, we 
can include real-time PCR; digital PCR (dPCR); 
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droplet digital PCR (ddPCR); beads, emulsions, 
amplification, and magnetics (BEAMing); and 
targeted next-generation sequencing (NGS).
In the untargeted approach, it is possible to 
investigate ctDNA without the knowledge of any 
specific mutations present in the primary tumor. 
This can be achieved through whole genome 
sequencing using NGS platforms. Nevertheless, 
this analysis is quite expensive and sometimes 
difficult to interpret; thus, it can be used for bio-
markers discovery in the context of disease mon-
itoring, detection of molecular resistance, and 
identification of new therapeutic targets. Despite 
whole genome sequencing, a more cost-effective 
method in the exome sequencing, which does not 
require prior knowledge of the genetic landscape 
of the tumor.
As previously mentioned, the main targeted 
approaches are real-time PCR, dPCR, ddPCR, 
BEAMing [16], and targeted NGS. Real-time 
PCR represents the oldest technique, but its sen-
sitivity has been dramatically improved thanks to 
the introduction of the ARMS technology (ampli-
fication refractory mutation system) [17, 18]. 
Nevertheless, the power of this technique in 
detecting mutant allele at a very low frequency is 
limited, and therefore other more sophisticated 
methods have been developed. Through the 
dPCR approach, the DNA sample is partitioned 
into thousands of single PCR reactions, improv-
ing detection power [19]. In ddPCR, the parti-
tioning is obtained through an emulsion PCR, 
each generated droplets ideally represent a PCR 
reactor. At the end of the analysis, software 
allows to identify a positive or a negative signal 
indicating the presence or absence of a target 
sequence. Therefore, a mutated ctDNA can be 
detected in a wide background of wild-type 
sequences. The dPCR platforms now available 
are various, each of them with a more or less dif-
ferent workflow, but they all share a very high 
sensitivity [20].
NGS is emerging as a very interesting tech-
nique because it has revolutionized our approach 
to molecular testing, indeed we can analyze mul-
tiple genes and multiple patients at a time with a 
consistent reduction in time and money. Of great 
interest, there is the paper of Newman et al. that 
has developed cancer personalized profiling by 
deep sequencing (CAPP-Seq) [21]. CAPP-Seq 
Fig. 6.1 Targeted and untargeted approaches for circulating DNA and circulating miRNAs evaluation
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method is able to detect ctDNA in 100% of 
patients with stage II–IV non–small-cell lung car-
cinoma and in 50% of patients with stage I. The 
diagnostic specificity was 96% for mutant allele 
fractions down to approximately 0.02% [21].
 Circulating MicroRNA
The promising role of circulating miRNAs as dis-
ease biomarkers has been deeply evaluated and 
still continues to increase the interest of scien-
tists. However, the technical aspects of miRNAs 
isolation, measurement, and quantification still 
represent the critical steps of circulating miRNAs 
analysis. Indeed, sample processing, isolation, 
hemolysis in blood samples, the lack of stable 
reference gene, and the wide variety of genome 
platforms are only a few of the many not negli-
gible aspects [22].
In circulating miRNAs analysis, the first and 
pivotal step is to identify a feasible source of 
nucleic acids. As reported in the study of Weber 
et al., the most common source of circulating 
miRNAs are plasma, serum, urine, and saliva 
but also microvesicles and exosomes [23]. Even 
if the exosomal miRNAs can probably provide 
more information, their isolation is complex 
[24]. The isolation of circulating miRNAs from 
plasma or serum is easier despite the high con-
tent of blood components in these body fluids. 
Furthermore, plasma and serum specimens 
often show a different spectrum of miRNAs also 
within the same individuals. Serum seems to be 
better source for miRNA isolation because the 
yield of miRNA is greater than the one obtained 
from plasma; this is probably due to the con-
tamination of RNAs deriving from platelets dur-
ing the clotting process [25]. Also in plasma, the 
levels of miRNA could be influenced by hemo-
lysis as recently reported by Kirschner et al. In 
fact, miR- 16 and miR-451 plasma levels are 
highly increased as usually they are in blood 
cells [26, 27]. Generally, the concentration of 
miRNAs in body fluids is very low. Therefore, 
the isolation and enrichment of miRNAs is an 
extremely delicate and important procedure. 
Nowadays, for the RNAs isolation we can rely 
on manual extraction methods such as the phe-
nol/chloroform or commercially distributed 
kits. Overall, they show differential efficiency 
even if the phenol/chloroform method showed 
higher yields (400 ng/500 uL of plasma) if com-
pared to the commercial kits (50 ng/200 uL of 
plasma) [28, 29]. Given the low representation 
of miRNAs in body fluids, another crucial step 
is represented by quantification. To date, many 
different quantitative approaches have been 
tested to analyze circulating miRNAs. One of 
the most commonly used approaches for the 
quantification of a specific miRNA is quantita-
tive real-time PCR (qRT-PCR). It can rely on 
two different strategies:
 1. Relative quantification: the relative expression 
of a specific miRNA is measured by comparing 
its level with the expression levels of a refer-
ence endogenous gene. Unfortunately, the 
debate on the most reliable endogenous miRNA 
is still open. Indeed, some groups speculate on 
the high reliability of miR-16, which expres-
sion levels are highly stable in different tissues, 
while some others demonstrated inconsistent 
expression of miR-16 in plasma and serum [30, 
31]. However, a combination of several genes 
among all those selected seems to be the best 
approach to follow [32].
 2. Absolute quantification: this method relies on 
the generation of a standard curve. The results 
of absolute quantification are often indicated 
as copies per uL of plasma or serum. In the 
last years, the introduction of digital technolo-
gies (dPCR, ddPCR) has deeply increased the 
sensibility of the standard PCR approaches. 
Indeed, without the aid of a standard curve, 
PCR-positive and PCR-negative reactions are 
counted and then the result is converted as 
number of copies of the specific target.
Regarding the expression profile of circulating 
miRNAs, the most commonly used platform is 
TaqMan Low Density Array (TLDA, 
ThermoFisher) based on qRT-PCR. This high- 
sensitive platform allows analyzing up to 754 
miRNAs at the same time. Generally, the 382- well 
format is the most developed for its reduced costs, 
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high throughput, and simple workflow. Moreover, 
its high sensibility allows the use of a low input of 
RNA (1-500 ng) [33, 34]. Another platform used 
for miRNAs profile is Microarray technology. 
Microarray is based on the hybridization of nucleic 
acids on different supports and for its less sensitiv-
ity, generally requires a higher RNA input (100 ng-
1ug) that probably represents the major limitation 
of this application. Moreover, it can often be diffi-
cult to discriminate mature from immature miR-
NAs forms due to background and 
cross-hybridization issues [35, 36]. The recent 
introduction of deep sequencing miRNAs 
(miRNA-seq), a NGS approach, allowed not only 
to assess miRNA expression levels but also to 
identify unknown miRNAs. The major limitation 
of using routinely NGS is strictly correlated to its 
high costs as well as time consuming. Moreover, it 
generally requires big amount of input RNA even 
if there are attempts to work with less starting 
material (5 ng). Nowadays, the most popular NGS 
technology used for circulating miRNAs analysis 
is Solexa sequencing by Illumina [37, 38]. 
Recently, a novel technology combining serial 
analysis of gene expression (SAGE) with NGS 
technology has been developed. The so- called 
digital gene expression (DGE) allows to simulta-
neously study novel potential miRNAs and ana-
lyze their expression level [22]. In conclusion, the 
choice of the proper platform to analyze circulat-
ing miRNAs strictly depends on the aim and con-
ditions of the study.
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